SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001628280-24-018773
Filing Date
2024-04-29
Accepted
2024-04-29 06:30:21
Documents
15
Period of Report
2024-04-29
Items
Item 7.01: Regulation FD Disclosure
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K xfor-20240429.htm   iXBRL 8-K 40409
2 EX-99.1 ex-991x4pressrelease4x29x24.htm EX-99.1 30343
6 image_0a.jpg GRAPHIC 14717
  Complete submission text file 0001628280-24-018773.txt   233494

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT xfor-20240429.xsd EX-101.SCH 1904
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT xfor-20240429_lab.xml EX-101.LAB 23449
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT xfor-20240429_pre.xml EX-101.PRE 13583
18 EXTRACTED XBRL INSTANCE DOCUMENT xfor-20240429_htm.xml XML 2824
Mailing Address 61 NORTH BEACON STREET 4TH FLOOR BOSTON MA 02134
Business Address 61 NORTH BEACON STREET 4TH FLOOR BOSTON MA 02134 857-529-8300
X4 Pharmaceuticals, Inc (Filer) CIK: 0001501697 (see all company filings)

IRS No.: 273181608 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38295 | Film No.: 24886456
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)